Cargando…

The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

This cohort study investigates the association between low levels of ERBB2 expression and progression-free survival among patients with HR+/ERBB2− metastatic breast cancer treated with CDK4/6 inhibitors.

Detalles Bibliográficos
Autores principales:	Bao, Kelvin K. H., Sutanto, Leone, Tse, Shirley S. W., Man Cheung, Ka, Chan, Jeffrey C. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571658/ https://www.ncbi.nlm.nih.gov/pubmed/34739066 http://dx.doi.org/10.1001/jamanetworkopen.2021.33132

Ejemplares similares

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases
por: Spencer, Kathryn S.R., et al.
Publicado: (2000)

Negative regulation of ErbB family receptor tyrosine kinases
por: Sweeney, C, et al.
Publicado: (2004)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
por: Kim, Min A, et al.
Publicado: (2011)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

ERBB4 confers metastatic capacity in Ewing sarcoma
por: Mendoza-Naranjo, Ariadna, et al.
Publicado: (2013)

ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report
por: Minuto, Michele, et al.
Publicado: (2018)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells
por: Valabrega, G, et al.
Publicado: (2003)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
por: Wandinger, Sebastian K., et al.
Publicado: (2016)

Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer
por: Ortega-Cava, Cesar F., et al.
Publicado: (2011)

Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis
por: Xia, Wenle, et al.
Publicado: (2014)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis
por: Hong, Se-Hoon, et al.
Publicado: (2016)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
por: Zoi, Ilianna, et al.
Publicado: (2019)

NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells
por: Miano, Carmen, et al.
Publicado: (2022)

Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo
por: Lahlou, Hicham, et al.
Publicado: (2012)

Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Li, Xuanyi, et al.
Publicado: (2022)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
por: Gautam, Shailendra K., et al.
Publicado: (2020)

Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma
por: Meyers, Nora, et al.
Publicado: (2020)

Phosphotyrosine interactome of the ErbB-receptor kinase family
por: Schulze, Waltraud X, et al.
Publicado: (2005)

The ErbB receptor tyrosine kinases and their roles in cancer
por: Hynes, NE
Publicado: (2003)

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
por: Torres-Jiménez, Javier, et al.
Publicado: (2022)

Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas
por: Gulati, Sasha, et al.
Publicado: (2010)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors
por: Gee, Julia MW
Publicado: (2002)

Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2
por: Ghosh, Chinmoy, et al.
Publicado: (2023)

CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
por: Werr, Lisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ksgd21o6c68uhrr7kn47u66g59